Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EARLY ACS: Early Eptifibatide in NSTE-ACS
NCT00089895Phase 3Completed
- Sponsor
- Organon & Co.
- Start
- Nov 2004
- Primary completion
- Nov 2008
- Modality
- Peptides, Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in non–ST-segment elevation acute coronary syndrome (NSTE-ACS) comparing Early Eptifibatide with Placebo (2 arms). Primary endpoint: Incidence of the Composite of Death, Myocardial Infarction (MI), Recurrent Ischemia Requiring Urgent Revascularization (RI-UR), and Thrombotic Bail-out at 96 hours. Started Nov 2004; status: completed.
02
Drugs
eptifibatide
03
Conditions
non–ST-segment elevation acute coronary syndrome (NSTE-ACS)
Beyond the preview
Go deeper on NCT00089895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00089895.